Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 19 | 2024 | 814 | 3.470 |
Why?
|
| Cancer Survivors | 6 | 2021 | 213 | 2.010 |
Why?
|
| Weight Loss | 4 | 2023 | 481 | 1.350 |
Why?
|
| Motivation | 5 | 2024 | 318 | 1.180 |
Why?
|
| Self Efficacy | 5 | 2021 | 198 | 1.080 |
Why?
|
| Overweight | 4 | 2022 | 363 | 0.870 |
Why?
|
| Weight Reduction Programs | 2 | 2022 | 56 | 0.820 |
Why?
|
| Social Media | 1 | 2024 | 108 | 0.780 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 99 | 0.730 |
Why?
|
| Mindfulness | 1 | 2021 | 20 | 0.720 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2021 | 39 | 0.690 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 2518 | 0.690 |
Why?
|
| Text Messaging | 1 | 2020 | 33 | 0.680 |
Why?
|
| Mobile Applications | 1 | 2021 | 88 | 0.680 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 235 | 0.660 |
Why?
|
| Schools | 5 | 2023 | 218 | 0.600 |
Why?
|
| Diet | 2 | 2023 | 1138 | 0.590 |
Why?
|
| Muscle Strength | 1 | 2018 | 74 | 0.560 |
Why?
|
| Aging | 1 | 2023 | 1181 | 0.520 |
Why?
|
| Urban Population | 1 | 2018 | 228 | 0.520 |
Why?
|
| Obesity | 5 | 2022 | 2244 | 0.500 |
Why?
|
| Rural Population | 1 | 2018 | 257 | 0.490 |
Why?
|
| Health Behavior | 4 | 2020 | 383 | 0.490 |
Why?
|
| Neoplasms | 3 | 2022 | 2794 | 0.380 |
Why?
|
| Ecological Momentary Assessment | 2 | 2022 | 3 | 0.370 |
Why?
|
| Fitness Trackers | 2 | 2021 | 12 | 0.350 |
Why?
|
| Middle Aged | 13 | 2025 | 26676 | 0.340 |
Why?
|
| Quality of Life | 1 | 2019 | 1906 | 0.320 |
Why?
|
| Feasibility Studies | 3 | 2022 | 760 | 0.320 |
Why?
|
| Aged | 9 | 2024 | 19656 | 0.310 |
Why?
|
| Humans | 28 | 2025 | 125110 | 0.310 |
Why?
|
| Health Promotion | 2 | 2024 | 386 | 0.310 |
Why?
|
| Female | 17 | 2025 | 66704 | 0.240 |
Why?
|
| Adult | 12 | 2025 | 29459 | 0.240 |
Why?
|
| Deception | 1 | 2025 | 11 | 0.240 |
Why?
|
| Receptors, Opioid, mu | 1 | 2025 | 30 | 0.240 |
Why?
|
| Data Accuracy | 1 | 2025 | 25 | 0.230 |
Why?
|
| School Teachers | 2 | 2022 | 7 | 0.230 |
Why?
|
| Heuristics | 1 | 2024 | 3 | 0.220 |
Why?
|
| Leisure Activities | 1 | 2023 | 7 | 0.220 |
Why?
|
| Mexico | 1 | 2023 | 181 | 0.210 |
Why?
|
| Cooking | 1 | 2023 | 37 | 0.200 |
Why?
|
| Workplace | 2 | 2022 | 70 | 0.200 |
Why?
|
| Fatigue | 1 | 2024 | 188 | 0.200 |
Why?
|
| Students | 2 | 2024 | 247 | 0.200 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.190 |
Why?
|
| Survivors | 1 | 2024 | 339 | 0.180 |
Why?
|
| Technology | 1 | 2021 | 64 | 0.180 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 409 | 0.170 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 72 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1319 | 0.160 |
Why?
|
| Teaching | 1 | 2021 | 188 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1114 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 103 | 0.160 |
Why?
|
| Affect | 1 | 2020 | 156 | 0.160 |
Why?
|
| Models, Psychological | 1 | 2019 | 138 | 0.150 |
Why?
|
| Telemedicine | 1 | 2025 | 436 | 0.150 |
Why?
|
| Cognition | 1 | 2023 | 724 | 0.150 |
Why?
|
| Physical Education and Training | 3 | 2023 | 20 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 243 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 3675 | 0.140 |
Why?
|
| Pandemics | 2 | 2021 | 1112 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 584 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 681 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2018 | 256 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 427 | 0.120 |
Why?
|
| Communication | 1 | 2019 | 507 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1187 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.120 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2014 | 11 | 0.110 |
Why?
|
| Hemocyanins | 1 | 2014 | 27 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 26 | 0.110 |
Why?
|
| Male | 11 | 2025 | 61443 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 69 | 0.110 |
Why?
|
| Sleep | 3 | 2022 | 346 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2023 | 4821 | 0.110 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 177 | 0.100 |
Why?
|
| School Health Services | 2 | 2022 | 99 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6537 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3402 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2024 | 535 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 19414 | 0.070 |
Why?
|
| Smartphone | 1 | 2025 | 38 | 0.060 |
Why?
|
| Molecular Docking Simulation | 1 | 2025 | 110 | 0.060 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 105 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2004 | 116 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 160 | 0.050 |
Why?
|
| United States | 3 | 2025 | 10884 | 0.050 |
Why?
|
| Binding Sites | 1 | 2025 | 1305 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2004 | 290 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 117 | 0.050 |
Why?
|
| Protein Binding | 1 | 2025 | 1756 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2022 | 440 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 508 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 137 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 550 | 0.040 |
Why?
|
| Feedback | 1 | 2018 | 162 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 90 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 290 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 190 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 348 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1526 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 656 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 278 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 191 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3571 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 412 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1605 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2014 | 678 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12272 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9056 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 130 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 248 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 880 | 0.010 |
Why?
|
| Child | 1 | 2022 | 24610 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1400 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1496 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 1390 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 6302 | 0.010 |
Why?
|